CAR-T in DLBCL: 4-year follow-up data from ZUMA-1

Marta Palhas — Fri, 26 Feb 2021 14:08:28 +0000

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the four-year follow-up data from the pivotal ZUMA-1 trial of axicabtagene ciloleucel (axi-cel) in adult patients with refractory diffuse large B-cell lymphoma (DLBCL). The four-year overall survival rate among patients after a single infusion of axi-cel was 44%. These are very encouraging results considering the heavily pre-treated patient population included in the pivotal clinical trial. Furthermore, there were no additional toxicity signs reported in this long-term follow-up analysis. This interview took place during the 3rd European CAR T-cell Meeting.

Real-world efficacy & safety data: CAR-T in DLBCL

admin_vjr_user — Thu, 08 Oct 2020 14:08:13 +0000

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, comments on the key clinical trials involved in CAR T-cell therapy for the treatment of refractory diffuse large B-Cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

ZUMA-1 – VJRegenMed

CAR-T in DLBCL: 4-year follow-up data from ZUMA-1

Real-world efficacy & safety data: CAR-T in DLBCL